Anika Therapeutics (ANIK) Total Non-Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Total Non-Current Liabilities data on file, last reported at $178.7 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 5.9% year-over-year to $178.7 million in Q1 2026; TTM through Mar 2026 was $178.7 million, a 5.9% decrease from a year earlier, with the FY2025 full-year figure at $189.6 million, down 6.14% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $178.7 million, down from $189.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ANIK reached as high as $353.5 million in Q2 2022 and fell as low as $178.7 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $267.5 million across 5 years, with a median of $263.3 million in 2024.
• Across the five-year window, Total Non-Current Liabilities gained 2.11% in 2022 and declined 29.64% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $348.7 million in 2022, then slipped by 22.51% to $270.2 million in 2023, then declined by 25.26% to $202.0 million in 2024, then retreated by 6.14% to $189.6 million in 2025, then slipped by 5.75% to $178.7 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $178.7 million in Q1 2026, $189.6 million in Q4 2025, and $188.7 million in Q3 2025.